Literature DB >> 11181344

An ATP-binding cassette transporter and two rRNA methyltransferases are involved in resistance to avilamycin in the producer organism Streptomyces viridochromogenes Tü57.

G Weitnauer1, S Gaisser, A Trefzer, S Stockert, L Westrich, L M Quiros, C Mendez, J A Salas, A Bechthold.   

Abstract

Three different resistance factors from the avilamycin biosynthetic gene cluster of Streptomyces viridochromogenes Tü57, which confer avilamycin resistance when expressed in Streptomyces lividans TK66, were isolated. Analysis of the deduced amino acid sequences showed that AviABC1 is similar to a large family of ATP-binding transporter proteins and that AviABC2 resembles hydrophobic transmembrane proteins known to act jointly with the ATP-binding proteins. The deduced amino acid sequence of aviRb showed similarity to those of other rRNA methyltransferases, and AviRa did not resemble any protein in the databases. Independent expression in S. lividans TK66 of aviABC1 plus aviABC2, aviRa, or aviRb conferred different levels of resistance to avilamycin: 5, 10, or 250 microg/ml, respectively. When either aviRa plus aviRb or aviRa plus aviRb plus aviABC1 plus aviABC2 was coexpressed in S. lividans TK66, avilamycin resistance levels reached more than 250 microg/ml. Avilamycin A inhibited poly(U)-directed polyphenylalanine synthesis in an in vitro system using ribosomes of S. lividans TK66(pUWL201) (GWO), S. lividans TK66(pUWL201-Ra) (GWRa), or S. lividans TK66(pUWL201-Rb) (GWRb), whereas ribosomes of S. lividans TK66 containing pUWL201-Ra+Rb (GWRaRb) were highly resistant. aviRa and aviRb were expressed in Escherichia coli, and both enzymes were purified as fusion proteins to near homogeneity. Both enzymes showed rRNA methyltransferase activity using a mixture of 16S and 23S rRNAs from E. coli as the substrate. Coincubation experiments revealed that the enzymes methylate different positions of rRNA.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181344      PMCID: PMC90357          DOI: 10.1128/AAC.45.3.690-695.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Evernimicin binds exclusively to the 50S ribosomal subunit and inhibits translation in cell-free systems derived from both gram-positive and gram-negative bacteria.

Authors:  P M McNicholas; D J Najarian; P A Mann; D Hesk; R S Hare; K J Shaw; T A Black
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

2.  Mutations in ribosomal protein L16 conferring reduced susceptibility to evernimicin (SCH27899): implications for mechanism of action.

Authors:  P V Adrian; W Zhao; T A Black; K J Shaw; R S Hare; K P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2000-03       Impact factor: 5.191

3.  Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group.

Authors:  R N Jones; S A Marshall; M E Erwin
Journal:  Diagn Microbiol Infect Dis       Date:  1999-06       Impact factor: 2.803

4.  Function of glycosyltransferase genes involved in urdamycin A biosynthesis.

Authors:  A Trefzer; D Hoffmeister; E Künzel; S Stockert; G Weitnauer; L Westrich; U Rix; J Fuchser; K U Bindseil; J Rohr; A Bechthold
Journal:  Chem Biol       Date:  2000-02

Review 5.  ABC transporters in antibiotic-producing actinomycetes.

Authors:  C Méndez; J A Salas
Journal:  FEMS Microbiol Lett       Date:  1998-01-01       Impact factor: 2.742

6.  Evernimicin (SCH27899) inhibits both translation and 50S ribosomal subunit formation in Staphylococcus aureus cells.

Authors:  W S Champney; C L Tober
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  High efficiency intergeneric conjugal transfer of plasmid DNA from Escherichia coli to methyl DNA-restricting streptomycetes.

Authors:  F Flett; V Mersinias; C P Smith
Journal:  FEMS Microbiol Lett       Date:  1997-10-15       Impact factor: 2.742

8.  In vivo activity and pharmacokinetics of ziracin (SCH27899), a new long-acting everninomicin antibiotic, in a murine model of penicillin-susceptible or penicillin-resistant pneumococcal pneumonia.

Authors:  E Wang; M Simard; Y Bergeron; D Beauchamp; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Pharmacokinetics of an everninomicin (SCH 27899) in mice, rats, rabbits, and cynomolgus monkeys following intravenous administration.

Authors:  C Lin; S Gupta; D Loebenberg; M N Cayen
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

Review 10.  Pharmacologic and bacteriologic properties of SCH-27899 (Ziracin), an investigational antibiotic from the everninomicin family.

Authors:  D R Foster; M J Rybak
Journal:  Pharmacotherapy       Date:  1999-10       Impact factor: 4.705

View more
  7 in total

1.  Interaction of avilamycin with ribosomes and resistance caused by mutations in 23S rRNA.

Authors:  Christine B Kofoed; Birte Vester
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

Review 2.  Avoidance of suicide in antibiotic-producing microbes.

Authors:  Eric Cundliffe; Arnold L Demain
Journal:  J Ind Microbiol Biotechnol       Date:  2010-05-06       Impact factor: 3.346

3.  Avilamycin and evernimicin induce structural changes in rProteins uL16 and CTC that enhance the inhibition of A-site tRNA binding.

Authors:  Miri Krupkin; Itai Wekselman; Donna Matzov; Zohar Eyal; Yael Diskin Posner; Haim Rozenberg; Ella Zimmerman; Anat Bashan; Ada Yonath
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-19       Impact factor: 11.205

Review 4.  Antimicrobial growth promoters used in animal feed: effects of less well known antibiotics on gram-positive bacteria.

Authors:  Patrick Butaye; Luc A Devriese; Freddy Haesebrouck
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

5.  Structures of the orthosomycin antibiotics avilamycin and evernimicin in complex with the bacterial 70S ribosome.

Authors:  Stefan Arenz; Manuel F Juette; Michael Graf; Fabian Nguyen; Paul Huter; Yury S Polikanov; Scott C Blanchard; Daniel N Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-21       Impact factor: 11.205

6.  Optimal Regimens and Clinical Breakpoint of Avilamycin Against Clostridium perfringens in Swine Based on PK-PD Study.

Authors:  Anxiong Huang; Xun Luo; Zihui Xu; Lingli Huang; Xu Wang; Shuyu Xie; Yuanhu Pan; Shiwei Fang; Zhenli Liu; Zonghui Yuan; Haihong Hao
Journal:  Front Pharmacol       Date:  2022-02-24       Impact factor: 5.810

Review 7.  Microbial Oligosaccharides with Biomedical Applications.

Authors:  Jian-Lin Xu; Zhi-Feng Liu; Xiao-Wei Zhang; Hai-Li Liu; Yong Wang
Journal:  Mar Drugs       Date:  2021-06-21       Impact factor: 5.118

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.